STEPHANIE TATE: Open Payments
NPI 1134875412 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,619 in 213 payments from 18 companies in 2025. Trend: 2023 $3,073 · 2024 $3,117 · 2025 $4,619
Food & beverage: $4,619
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 61 | $1,355 |
| Madrigal Pharmaceuticals | 20 | $792 |
| Janssen Biotech, Inc. | 22 | $621 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 33 | $450 |
| Regeneron Healthcare Solutions, Inc. | 9 | $227 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $202 |
| Phathom Pharmaceuticals, Inc. | 16 | $156 |
| Ardelyx, Inc. | 7 | $141 |
| QOL Medical, LLC | 5 | $135 |
| Gilead Sciences, Inc. | 6 | $111 |
Products named: REZDIFFRA, RINVOQ, TREMFYA, SKYRIZI, XIFAXAN, DUPIXENT, ENTYVIO, VOQUEZNA.
Industry payments across AL — which companies pay providers there.
